CD274 and head and neck squamous cell carcinoma: A meta-analysis showed that none of the alternative treatments demonstrated significant advantages over the standard concurrent CRT; some studies found that adding PD-1/PD-L1 inhibitors to standard therapy does not enhance 1- or 2-year survival for patients with local advanced HNSCC [29].